Osteoporosis is traditionally regarded as a disease of elderly women. However, this bone disorder occurs in patients of both sexes and of all ages and is also increasingly recognised in the paediatric setting. In particular, patients, including young children, with other chronic diseases are at risk of developing bone fragility. There are also several forms of hereditary osteoporosis, which should be identified at an early stage to ensure adequate treatment. The diagnosis of osteoporosis in children is challenging, since their bone mineral density (BMD) is affected by growth and pubertal development. In addition to low BMD, a child must also exhibit a significant proneness to fractures before the osteoporosis diagnosis can be made. Through early diagnosis and treatment for paediatric bone fragility, we can also ameliorate bone health in adulthood. In this article we review the aetiology, known risk factors and the diagnostic criteria of osteoporosis in the young.
Osteoporosis and related fragility fractures are a significant cause of morbidity and mortality in developed countries. 1 The lifetime risk of osteoporosis-related fractures exceeds 40 % in women and 20 % in men. 2 According to the definition set by the World Health Organization (WHO), osteoporosis is defined as a "systemic skeletal disease characterized by low bone mass and micro-architectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fractures", 1 and arises when the amount of bone resorbed exceeds the amount of newly formed bone inducing a net loss of bone mass.
New bone is formed and old bone is degraded continuously throughout life. The most rapid bone mass accrual occurs around puberty, and approximately 90 % of the maximum bone mass in life, the peak bone mass (PBM), is acquired before the age of 20 years. 3, 4 The PBM achieved in youth is an important predictor of osteoporosis in adulthood and affects the time of onset of osteoporosis; a 10 % increase in PBM has been estimated to delay the onset of postmenopausal osteoporosis by up to 13 years. 5, 6 Therefore, the optimal time to intervene with regards to prevention of osteoporosis is, in fact, in adolescence.
Aetiology
Osteoporosis occurs in both sexes and in individuals of all ages, and is generally divided into primary and secondary osteoporosis (see Table 1 ). The most common form of primary osteoporosis is seen in the elderly, where bone fragility is age-related and associated with a decline in sex hormones. In younger patients, primary osteoporosis is mainly hereditary, and genetic factors are estimated to account for up to 80 % of the variance in PBM. 7 The most common form of primary osteoporosis is osteogenesis imperfecta (OI), caused by mutations in the genes encoding collagen type I and related peptides. 8, 9 Many other genetic forms have been identified, but these are rare (summarised in Table 2 ). As the genetic cause of most cases remains unknown, these are termed idiopathic. Mutations in two genes, LRP5 and WNT1, have been identified as the cause of dominantly inherited osteoporosis without other phenotypic features, and more causative genes will probably be found in time. 10, 11 Genetic screening for mutations in these genes is currently in use mainly in research settings.
Secondary osteoporosis is due to underlying chronic illness or its treatment, which decreases bone strength and predisposes the patient to fragility fractures. The most common form of secondary osteoporosis arises from long-term use of glucocorticoids, which even at low dosages causes a significant decrease in BMD. 12 Other conditions associated with an increased fracture risk and osteoporosis in children include endocrine disturbances, inflammatory diseases, certain forms of cancer and associated treatments, immobilisation and haematological disorders ( Table 1) . Additional risk factors, such as limited physical activity and nutrition (especially low intake of vitamin D, calcium and proteins) also affect bone mass accrual in both healthy and chronically ill children. 6, 13, 14 The Use Of DXA in Children and Adolescents diagnosis of osteoporosis in a child or adolescent requires the presence of both a clinically significant fracture history and low areal BMD or BMC for chronological age (see Table 3 ). 28 Therapeutic interventions should not be initiated based on one DXA measurement alone. 29 
Additional Considerations in Clinical Practice

Initiation of and Follow-up with DXA Scan Measurements
When meeting a child with suspected bone fragility or at risk of bone fragility based on clinical history, when should DXA measurements commence? According to the recommendations of ISCD, 29 a DXA screening should be performed at clinical presentation of primary osteoporosis (mainly OI or idiopathic osteoporosis), or of a disease that puts the child at risk of secondary osteoporosis, e.g. endocrine disturbances, chronic inflammatory diseases, after organ transplantation and childhood cancer. The screening should include spine and TBLH areal BMD and BMC when technically feasible. In children with chronic immobilisation or significant motor disability, DXA screening should be performed at fracture presentation. Data regarding the risk of fragility fractures in children with thalassaemia are in part contradictory, and screening is recommended to begin at fracture presentation or at the latest at the age of 10 years. Women with Turner's syndrome rarely fracture in childhood and therefore no general screening is recommended in childhood or adolescence based on the genetic diagnosis. 29 There are no clear-cut recommendations in terms of the frequency or length of DXA follow-up measurements. Children with idiopathic osteoporosis may show a spontaneous normalisation of BMD after puberty, 30 while adolescents with anorexia nervosa and related endocrine disturbances may never achieve a normal PBM and have an increased risk of fracture up to 40 years after the diagnosis. 31, 32 A baseline value prior to bone-active treatments, such as bisphosphonates and growth hormone, should be obtained and follow-up measurements performed to monitor treatment response at clinically appropriate intervals. The recommended minimum time interval for follow-up measurements during treatment or disease progress is six months to avoid excessive exposure to radiation. 
Risk of Vertebral Fractures in Children at Risk of Secondary Osteoporosis
If vertebral fractures unrelated to high-impact trauma are diagnosed in children, these usually signify a significant skeletal pathology. Vertebral compression fractures are surprisingly common in chronically ill children; the prevalence is 8-25 % among children with rheumatoid arthritis, leukaemia, after organ transplants or of children with motor disabilities. [33] [34] [35] [36] [37] Compression fractures are underdiagnosed in this group of patients, as most children have no symptoms. New DXA equipment often offers the possibility to assess vertebral morphology, but despite high diagnostic accuracy of this method in adults, up to two-thirds of compression fractures in children are missed.
38 Spine X-rays or magnetic resonance imaging should therefore be considered in chronically ill children with back problems.
Prevention and Treatment of Osteoporosis in Children and Adolescents
Although the main determinants of PBM acquisition are genetic and/or affected by other diseases and related treatments, we can affect the factors amenable to positive intervention in growing children. thereafter is 600-1,000 IU daily, aiming at blood levels of 25(OH)D between 30 and 50 ng/ml. Some patients may need two to three times higher doses to achieve sufficient serum levels. 40 If the preventative measures are insufficient in terms of osteoporosis and fractures, the question may arise as to whether bone-active agents should be prescribed. While the efficacy and safety of such treatments are rather well documented in the adult population, the data regarding treatment of children are scarcer. The only anabolic bone therapy available, recombinant parathyroid hormone, is not approved for children as it has caused osteosarcoma in growing rodents. 41 A group of anti-catabolic bone-active agents, namely bisphosphonates, remains the only alternative.
While treatment with bisphosphonates is becoming quite widespread in children with OI, the effects in children with secondary osteoporosis are less well-known. There is a shortage of data regarding the efficacy, safety, choice of agent, duration of treatment and long-term outcome. 39 Therefore, treatment with bone-active agents in children should be conducted only in large paediatric centres and preferably in the setting of clinical trials.
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Conclusions
The diagnosis of osteoporosis in a growing child cannot be set based on bone densitometric measurements only, but requires both a significant fracture history and low areal BMD or BMC.
Vertebral compression fractures are common and underdiagnosed in children with secondary osteoporosis.
The need for supplementation with calcium and vitamin D should be assessed and addressed in all children at risk of osteoporosis.
Treatment with bone-active agents, such as bisphosphonates, should be conducted at paediatric centres with sufficient experience of treatment and follow-up of children with metabolic bone diseases. n
